Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of DS-8201a in advanced or metastatic solid tumors
CTR20254938Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254938.